Plate Nº 88 · recorded September 30, 2026
Health & Medicine ResearchReported finding
Two-Drug Combo May Force Aggressive Kidney Cancer to Self-Destruct
Lab studies show belzutifan plus engineered TRAIL protein can free hidden death receptors and drive aggressive kidney cancer cells to self-destruct.
By Marcus Bennett4 min read724 words
In brief
- Notre Dame researchers found that combining the FDA-approved drug belzutifan with lab-made TRAIL protein significantly increased tumor cell death in lab tests and animal models of clear cell renal cell carcinoma, the most aggressive kidney cancer.
- Loss of the VHL tumor suppressor gene activates HIF-2-alpha, which overproduces natural TRAIL inside the cell, trapping death receptors deep inside and speeding tumor growth; belzutifan reduces HIF-2-alpha, returning receptors to the surface where recombinant TRAIL can trigger apoptosis.
- The study, published in the Proceedings of the National Academy of Sciences (2026), is preclinical; the combination has not yet been tested in human trials.
A genetic weak point in clear cell renal cell carcinoma — the most aggressive form of kidney cancer — may open the door to a two-part treatment that pushes tumor cells to destroy themselves, according to new research published in the Proceedings of the National Academy of Sciences.
The findings come from Xin Lu, the John M. and Mary Jo Boler Collegiate Professor and associate chair in the Department of Biological Sciences at the University of Notre Dame, together with collaborators at Notre Dame and the University of Galway in Ireland.
The resistance problem
The study centers on the drug belzutifan, sold under the brand name Welireg. Belzutifan works partially against clear cell renal cell carcinoma, Lu explains, but it has a familiar weakness: some tumors resist the drug from the start, while others acquire resistance over time. That leaves patients and doctors with shrinking options.
Lu's team found a way around this resistance by pairing belzutifan with a laboratory-made version of a protein called TRAIL — short for tumor necrosis factor-related apoptosis-inducing ligand. In laboratory tests and in animal models, the combination sharply increased the death of tumor cells.
A protein that hides its own kill switch
The mechanism hinges on a gene most people associate with this cancer. Most patients with clear cell renal cell carcinoma have von Hippel-Lindau (VHL) syndrome, caused by a mutation in the VHL tumor suppressor gene, although others can develop the disease too.
Lu and his colleagues discovered that losing the VHL gene switches on another protein, HIF-2-alpha. This protein drives the cell to produce high levels of its own natural TRAIL. TRAIL normally triggers apoptosis — the programmed self-destruction of a cell — by locking onto "death receptors" sitting on the cell's surface.
Here is the twist: when the cell makes too much of its own TRAIL, that excess protein traps the death receptors deep inside the cell, where outside treatments cannot reach them. The abundant TRAIL also accelerates the cell cycle, so the tumor grows faster. In effect, the cancer weaponizes a protein that should kill it.
Revealing the hidden targets
The combination therapy reverses that trap. Belzutifan reduces HIF-2-alpha. That, in turn, lowers the amount of natural TRAIL inside the cell, freeing the buried death receptors and shuttling them back to the cell surface, according to Lu, who is also affiliated with the Institute for Rare Diseases, the Berthiaume Institute for Precision Health, and the Harper Cancer Research Institute.
With the receptors exposed, the researchers then introduced the recombinant TRAIL — essentially a lab-built copy of the protein — which latched onto the newly available receptors and triggered cell death.
"This is really kind of magical, because when you reduce TRAIL, you can reduce cell division, cell proliferation, and make the cell more vulnerable to apoptosis," Lu said. "You really kind of force the cells into this corner where they can't divide well."
A realistic path to patients
The strategy has a practical advantage: both components already exist in the clinical pipeline. The U.S. Food and Drug Administration has approved belzutifan, and therapies that activate TRAIL are currently moving through clinical trials. That means the combination could reach patients faster than a drug developed from scratch.
Clinicians, for their part, appear eager for exactly this kind of advance. When Lu presented the work at a major urology conference, "the physicians, they're excited about this," he said. "They all know this belzutifan resistance is something they have to overcome."
Important caveats
The results so far come from laboratory tests and preclinical models, not from human trials. Promising cell and animal data often fail to translate into patient benefits, so the true test will be clinical studies of the belzutifan–TRAIL pairing in people with clear cell renal cell carcinoma. How the approach performs against tumors that are inherently resistant to belzutifan, and whether recombinant TRAIL can be delivered safely at effective doses, remain open questions.
Still, for a cancer notorious for its aggressiveness and its knack for evading treatment, the work points to a new route: turning the disease's own genetics against it.
The paper appears as Xuechun Wang et al., "Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma," Proceedings of the National Academy of Sciences (2026), DOI: 10.1073/pnas.2535452123.
via Medical Xpress (Source)
More from Marcus Bennett
Nearby plates
- Lung Cancers Evade KRAS Drugs by Switching Cell Type
- Enzyme's Hidden Second Job May Drive Breast Cancer Drug Resistance
- Same-Day Chemotherapy Turns Into a Booster for Cancer Vaccines
- Immune Cells Blur the Line Between Innate and Adaptive Defenses
- Scientists Map Three Weak Points in Antibiotic-Resistant Bacteria